- Home
- NIVF vs QNRX Comparison
NIVF vs QNRX Comparison
Compare NIVF & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- QNRX
- Stock Information
- Founded
- NIVF 2011
- QNRX 2018
- Country
- NIVF Hong Kong
- QNRX United States
- Employees
- NIVF N/A
- QNRX 4
- Industry
- NIVF
- QNRX Medical/Dental Instruments
- Sector
- NIVF
- QNRX Health Care
- Exchange
- NIVF NYSE
- QNRX Nasdaq
- Market Cap
- NIVF 5.0M
- QNRX 4.8M
- IPO Year
- NIVF N/A
- QNRX N/A
- Fundamental
- Price
- NIVF $0.28
- QNRX $0.43
- Analyst Decision
- NIVF
- QNRX Strong Buy
- Analyst Count
- NIVF 0
- QNRX 1
- Target Price
- NIVF N/A
- QNRX $4.00
- AVG Volume (30 Days)
- NIVF 5.3M
- QNRX 544.2K
- Earning Date
- NIVF 02-16-2025
- QNRX 03-12-2025
- Dividend Yield
- NIVF N/A
- QNRX N/A
- EPS Growth
- NIVF N/A
- QNRX N/A
- EPS
- NIVF N/A
- QNRX N/A
- Revenue
- NIVF $5,679,218.00
- QNRX N/A
- Revenue This Year
- NIVF N/A
- QNRX N/A
- Revenue Next Year
- NIVF N/A
- QNRX N/A
- P/E Ratio
- NIVF N/A
- QNRX N/A
- Revenue Growth
- NIVF N/A
- QNRX N/A
- 52 Week Low
- NIVF $0.24
- QNRX $0.43
- 52 Week High
- NIVF $17.24
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- NIVF 36.38
- QNRX 38.68
- Support Level
- NIVF $0.29
- QNRX $0.56
- Resistance Level
- NIVF $0.38
- QNRX $0.63
- Average True Range (ATR)
- NIVF 0.05
- QNRX 0.07
- MACD
- NIVF -0.01
- QNRX -0.01
- Stochastic Oscillator
- NIVF 1.89
- QNRX 1.81
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.